Header

UZH-Logo

Maintenance Infos

Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma


Trojan, A; Tinguely, M; Vallet, S; Seifert, Burkhardt; Jenni, B; Zippelius, A; Witzens-Harig, M; Mechtersheimer, G; Ho, A; Goldschmidt, H; Jäger, D; Boccadoro, M; Ladetto, M (2006). Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Medical Weekly, 136(25-26):400-403.

Abstract

Several biological and clinical considerations suggest the involvement of cyclooxygenase-2 (COX-2), the key enzyme of prostaglandin (PG) synthesis, in the pathogenesis and progression of haematological malignancies. Despite the wealth of data concerning COX-2 expression, only limited information is available on multiple myeloma (MM). Using standard immunohistochemistry we therefore evaluated COX-2 protein expression in samples from 57 patients with a primary diagnosis of MM. Time to progression and a variety of clinicopathological features were evaluated by the Kaplan-Meier method and the Cox regression model. In addition, COX-2 expression was evaluated by staining bone marrow from healthy donors and 11 patients with MGUS. Overall, 31 MM samples (54%) expressed COX-2. Positivity for COX-2 was unrelated to stage or clinical or molecular features of the disease. However, patients with COX-2 positive tumours experienced a significantly shorter time to progression (17 vs 30 months, p = 0.037). In summary, COX-2 is frequently expressed in MM and correlates with shorter progression-free survival.

Abstract

Several biological and clinical considerations suggest the involvement of cyclooxygenase-2 (COX-2), the key enzyme of prostaglandin (PG) synthesis, in the pathogenesis and progression of haematological malignancies. Despite the wealth of data concerning COX-2 expression, only limited information is available on multiple myeloma (MM). Using standard immunohistochemistry we therefore evaluated COX-2 protein expression in samples from 57 patients with a primary diagnosis of MM. Time to progression and a variety of clinicopathological features were evaluated by the Kaplan-Meier method and the Cox regression model. In addition, COX-2 expression was evaluated by staining bone marrow from healthy donors and 11 patients with MGUS. Overall, 31 MM samples (54%) expressed COX-2. Positivity for COX-2 was unrelated to stage or clinical or molecular features of the disease. However, patients with COX-2 positive tumours experienced a significantly shorter time to progression (17 vs 30 months, p = 0.037). In summary, COX-2 is frequently expressed in MM and correlates with shorter progression-free survival.

Statistics

Citations

16 citations in Web of Science®
19 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

88 downloads since deposited on 20 May 2009
8 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2006
Deposited On:20 May 2009 07:25
Last Modified:02 Mar 2017 09:47
Publisher:EMH Swiss Medical Publishers
ISSN:0036-7672
Free access at:Official URL. An embargo period may apply.
Official URL:https://smw.ch/en/archives/article/?tx_ezmjournal_articledetail[identifier]=smw.2006.11467
PubMed ID:16847764

Download

Download PDF  'Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma'.
Preview
Content: Published Version
Filetype: PDF
Size: 367kB
Licence: Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)